AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00787527
Drug: Zolinza (vorinostat)
RxNorm normalized name: vorinostat Oral Capsule [Zolinza]
DrugBank: Vorinostat (DB02546)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Up to two 100 mg capsules of Vorinostat (dosage will vary from 100 mg orally (PO) twice daily (BID), 300 mg PO every evening and 200 mg PO BID with the starting dose at 300 mg PO every evening for the phase I trial) are to be administered orally twice daily (once in the morning and once in the evening, or if in the daily dosing cohort once in the evening) in repeated 21-day cycles consisting of 10 days dosing starting on days 5 through 14 followed by a 7-day rest period, during which no vorinostat will be administered.
Trial: NCT00787527
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.4 mg/m\^2 by vein over 15 minutes on Day 1 of 21 day cycle
Trial: NCT00787527
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg tablets by mouth once a day on Days 1-5 of 21 day cycle
Trial: NCT03762785
Drug: nebulized Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: inhalation of dexmedetomidine by nebulizer. the study drug will be prepared in 3 ml of 0.9% saline and will be administered by standard hospital jet nebulizer via face-mask with continuous flow of 100%oxygen at 6 l/m for 10 to 15 min
Trial: NCT02485873
Drug: Rivaroxaban (Xarelto, BAY59-7939)
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: As prescribed by treating physicians
Trial: NCT02973386
Drug: IMRT combine with cisplatin concurrent chemotherapy
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in the control arm received radical radiotherapy with IMRT, and cisplatin (100mg/m2 on day 1 and day 22) during RT.
Trial: NCT01068392
Drug: Oxaliplatin, Prednisolone
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: OXALIPLATIN+PREDNISOLONE (OX-P)~D1 Oxaliplatin 130mg/m2 + 5DW 500ml MIV over 2hr~D1-5 Prednisolone 40-30-30 mg/day P.O~every 3 weeks
Trial: NCT01438151
Drug: Remicade
RxNorm normalized name: Remicade
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The first potential for dose augmentation will be at infusion #3 (visit 1 and 2 patients will receive 5 mg/kg). Patients will be assessed at each infusion visit for response defined as a reduction in HBI score by 2 or more points from prior visit (unless in remission; HBI score of 4 or less). Patients with a response will be maintained at the dose where response was achieved. If there is no response to treatment, or flare at any visit (beginning at visit #3), infliximab dose or dosing frequency will be increased in a gradual fashion, up to a maximum of 15 mg/kg every 6 weeks, until response is achieved.
Trial: NCT01561014
Drug: erlotinib hydrochloride
RxNorm normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01561014
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02068365
Drug: Pegyinterferon-alfa-2a
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pegyinterferon-alfa-2a 180mcq weekly for 48 weeks
Trial: NCT00190710
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00190710
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02807051
Drug: Pacritinib
RxNorm normalized name: Pacritinib
DrugBank: Pacritinib (DB11697)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single 400-mg dose (four 100-mg capsules) administered in the morning on Days 1 and 12
Trial: NCT01049243
Drug: Fluocinonide Cream 0.1%
DrugBank: Fluocinonide (DB01047)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.1% Cream, One Application, Twice Daily, 14 Days
Trial: NCT01287364
Drug: ciclesonide hydrofluoroalkane (HFA) nasal aerosol
RxNorm normalized name: Ciclesonide Nasal Aerosol
DrugBank: Ciclesonide (DB01410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ciclesonide hydrofluoroalkane (HFA) nasal aerosol 80 μg once daily for one week.
Trial: NCT01287364
Drug: mometasone nasal inhalation
RxNorm normalized name: mometasone Inhalant Product
DrugBank: Mometasone (DB00764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mometasone nasal inhalation 200 μg once daily for one week
Trial: NCT01379573
Drug: Hydroxychloroquine
RxNorm normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nineteen women meeting eligibility criteria will receive 400mg per day of HCQ beginning as soon as pregnancy is established and informed consent obtained. Mothers already on HCQ will remain on 400mg, or escalate to 400mg if on 200mg. Hydroxychloroquine is taken in 200mg pill form - 400mg = 2 200mg pills.
Trial: NCT00283036
Drug: Irbesartan
RxNorm normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04582942
Drug: PEG
RxNorm normalized name: PEG
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients began to drink 1 L of PEG at 8:00 PM on the day before colonoscopy at a rate of 250 mL every 10- 15 minutes. On the day of the procedure, patients took the remaining 2 L of PEG 4-6 hours before colonoscopy.
Trial: NCT04582942
Drug: PEG+lactulose
RxNorm normalized name: Lactulose
DrugBank: Lactulose (DB00581)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: On the day before colonoscopy , Patients took 45 mL lactulose solution at 7:00 PM. And then Patients began to drink 1 L of PEG at 8:00 PM at a rate of 250 mL every 10- 15 minutes. On the day of the procedure, patients took 45 mL lactulose solution and the remaining 2 L of PEG 4-6 hours before colonoscopy.
Trial: NCT00324051
Drug: olanzapine therapy
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02214381
Drug: Myocet
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02214381
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT04240756
Drug: Extended release mixed amphetamine salts (MAS)
RxNorm normalized name: Amphetamine Mixed Salts Extended-Release Capsules
DrugBank: Amphetamine (DB00182)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The MAS protocol will include a 2-4 -week open-label titration beginning at 20 mg and dose level will be increased weekly at telehealth visits with the psychopharmacologist until an optimal response or maximum dose of 60 mg.
Trial: NCT04930133
Drug: Gilotrif
RxNorm normalized name: Gilotrif
DrugBank: Afatinib (DB08916)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: This is non-interventional, multi-center, multi-cohort study based on existing data from EGFR sensitizing mutation-positive NSCLC patients treated with afatinib as the first-line treatment. Enrolled patients will be categorized into four cohorts (cohort A, B, C and D) according to the type of second line treatment with biopsy results before start of second line treatment.
Trial: NCT05523648
Drug: Chronic Hepatitis B
RxNorm normalized name: HEPATITIS B
DrugBank: Hepatitis B immune globulin (DB05276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 92 patients included in the study were randomly divided into 2 groups, 42 patients in the control group and 50 patients in the treatment group. Both groups of patients received conventional basic treatment such as liver protection. Moreover, in both groups, patients were instructed to change their dietary structure to control low-fat and low-sugar, and were instructed to perform appropriate aerobic exercise.
Trial: NCT00107536
Drug: lapatinib ditosylate
RxNorm normalized name: Lapatinib Ditosylate
DrugBank: Lapatinib (DB01259)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00056472
Drug: Olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10-20mg/day
Trial: NCT00056472
Drug: Sertraline
RxNorm normalized name: Sertraline
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150-200mg/day
Trial: NCT02519777
Drug: Placebo for maraviroc (MVC)
RxNorm normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally as one 150 mg tablet BID OR two 300 mg tablet BID OR one 300 mg tablet BID depending upon background ARV regimen
Trial: NCT02519777
Drug: Placebo for dolutegravir (DTG)
RxNorm normalized name: dolutegravir Tablet for Oral Suspension
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered orally as one 50 mg tablet BID OR one 50 mg tablet QD depending upon background ARV regimen
Trial: NCT02519777
Drug: Dolutegravir (DTG)
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered orally as one 50 mg tablet BID OR one 50 mg tablet QD depending upon background ARV regimen
Trial: NCT02519777
Drug: Maraviroc (MVC)
RxNorm normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally as one 150 mg tablet BID OR two 300 mg tablet BID OR one 300 mg tablet BID depending upon background ARV regimen
Trial: NCT01440959
Drug: dovitinib
RxNorm normalized name: Dovitinib
DrugBank: Dovitinib (DB05928)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TKI258 at 500 mg/day on a 5 days on/2 days off dosing schedule
Trial: NCT02846506
Drug: Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC]
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will receive 1 XR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fed (Treatment B)or fasted condition (Treatment D) in a given treatment period as per treatment sequence.
Trial: NCT02846506
Drug: Canagliflozin 50 mg
RxNorm normalized name: canagliflozin 50 MG
DrugBank: Canagliflozin (DB08907)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive canagliflozin 50 mg oral tablet under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.
Trial: NCT02846506
Drug: Canagliflozin 100 mg
RxNorm normalized name: canagliflozin 100 MG
DrugBank: Canagliflozin (DB08907)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive canagliflozin 100 mg oral tablet under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.
Trial: NCT02903121
Drug: Tamoxifen
RxNorm normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamoxifen 10 mg orally twice daily for 7 days. Treatment to be started after 3 consecutive days of bleeding and can be repeated every 30 days two more times in the first 90 days of the study
Trial: NCT02903121
Drug: Tamoxifen (open label)
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamoxifen 10 mg orally twice daily for 7 days. Treatment to be started after 3 consecutive days of bleeding and can be repeated every 30 days two more times in the second 90 days of the study
Trial: NCT02846506
Drug: Metformin Extended Release (XR)
RxNorm normalized name: metformin Extended Release Suspension
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will receive metformin XR 500 mg tablet orally under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.
Trial: NCT03363854
Drug: Tralokinumab
RxNorm normalized name: tralokinumab
DrugBank: Tralokinumab (DB12169)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration.
Trial: NCT01430520
Drug: Escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tables with Escitalopram (10 mg), 1 tablet a day for 7 days, starting on the day of surgery
Trial: NCT02114099
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg qd x1 year
Trial: NCT04523207
Drug: Apalutamide
RxNorm normalized name: Apalutamide
DrugBank: Apalutamide (DB11901)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive apalutamide 240 mg (4 tablets of 60 mg each) oral tablets during the main study and sub-study.
Trial: NCT04523207
Drug: Relugolix
RxNorm normalized name: Relugolix
DrugBank: Relugolix (DB11853)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive 120 mg of relugolix following a loading dose of 360 mg of (3 tablets of 120 mg each) relugolix during the sub-study.
Trial: NCT02968134
Drug: Posaconazole
RxNorm normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: A single dose of 300mg intravenous posaconazole will be administered and blood samples will be taken prior to start of infusion, at 15,45,75minutes, 3,5,8,12,18,24,30,36 and 48 hours.
Trial: NCT05568082
Drug: AMG 510
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet
Trial: NCT05568082
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral capsule
Trial: NCT03501368
Drug: Ceritinib
RxNorm normalized name: Ceritinib
DrugBank: Ceritinib (DB09063)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will take ceritinib by mouth (PO) once daily at a dose of up to 450 mg (3 capsules of 150 mg)
Trial: NCT03501368
Drug: Trametinib
RxNorm normalized name: Trametinib
DrugBank: Trametinib (DB08911)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will take trametinib by mouth at a dose of 2 mg daily
Trial: NCT02398825
Drug: Ponatinib
RxNorm normalized name: Ponatinib
DrugBank: Ponatinib (DB08901)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ponatinib is given orally 30 mg daily, with dose adjustment to 15 mg daily once a BCR-ABL1 level minor or equal to 0.1% (MMR) has been achieved and confirmed in the next test, 4 weeks apart. A return to prior, 30 mg, dose is due in case of return of BCR-ABL1 transcripts level to \> 1%. Dose adjustments for toxicity are detailed in the protocol.
Trial: NCT03611153
Drug: AZD4831 Oral Myeloperoxidase Inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single administration dose of 30 mg oral MPO inhibitor given orally following baseline, resting and exercise testing in patients during right heart catheterization.
Trial: NCT03837977
Drug: Liposomal Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arm I
Trial: NCT03837977
Drug: Folinic Acid
RxNorm normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arm I
Trial: NCT03837977
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Arm II
Trial: NCT03791112
Drug: BPI-16350
RxNorm normalized name: BPI-3016
DrugBank: BPI-3016 (DB15158)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BPI-16350 capsules administered orally
Trial: NCT03264027
Drug: Carbon dioxide
RxNorm normalized name: Carbon Dioxide
DrugBank: Carbon dioxide (DB09157)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbon dioxide will be used as an insufflating gas during argon fulguration of the dilatated anastomosis.
Trial: NCT03264027
Drug: Ambient air
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambient air will be used as an insufflating gas during argon fulguration of the dilatated anastomosis.
Trial: NCT03264027
Drug: Argon fulguration
RxNorm normalized name: argon
DrugBank: 7-Keto-8-Aminopelargonic Acid (DB02274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dilatated anastomosis from the gastric bypass surgery will be reduced in diameter using fulguration with argon. Patient in both groups will be placed in the left lateral decubitus position, with anesthesia being performed exclusively using propofol; adequate cardiopulmonary monitoring will be carried out during the entire procedure. After sedation, endoscopy will be performed with an Olympus CV-180 endoscope (Olympus, Tokyo, Japan) and analysis and measurement of the anastomosis will be achieved using Raptor foreign body forceps (Endoscopy Group US, Inc., Mentor - Ohio, USA). The images will be transferred to an Olympus EvisExera II processor connected to a computer with the ZScan 5 program (Goiânia, GO, Brazil).
Trial: NCT03704428
Drug: SHR-1314
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Injection solution. Route of administration: subcutaneous injection.
Trial: NCT03316898
Drug: Donepezil
RxNorm normalized name: Donepezil
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Donepezil 10 mg as prescribed by the physician as per standard of care.
Trial: NCT03316898
Drug: Memantine
RxNorm normalized name: Memantine
DrugBank: Memantine (DB01043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Memantine as prescribed by the physician as per standard of care.
Trial: NCT03570476
Drug: Olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given orally
Trial: NCT03147612
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given intrathecally or IV
Trial: NCT03147612
Drug: Ponatinib
RxNorm normalized name: Ponatinib
DrugBank: Ponatinib (DB08901)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01070511
Drug: Tadalafil
RxNorm normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tadalafil will be administered orally on two consecutive days. The first dose-10 mg- will be administered the afternoon before the study. The second dose -20 mg-will be administered the morning of the study.
Trial: NCT02476617
Drug: ombitasvir/paritaprevir/ritonavir
RxNorm normalized name: ombitasvir/paritaprevir/ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ombitasvir/ABT-450/ritonavir tablets
Trial: NCT03147612
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02476617
Drug: dasabuvir
RxNorm normalized name: Dasabuvir
DrugBank: Dasabuvir (DB09183)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: dasabuvir tablets
Trial: NCT02476617
Drug: ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ribavirin tablets
Trial: NCT01254136
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: INCB007839 tablets (300 mg BID) in combination with trastuzumab and vinorelbine will be administered in an initial Cycle of 28 days and followed by continuous 21-day cycles subsequently. Trastuzumab will be administered in continuous 21-day cycles beginning on Day 8 of Cycle 1. Vinorelbine will be administered on a weekly schedule for a minimum of the first four cycles beginning on Cycle 1 Day 8. All drugs will be administered continuously as tolerated or until a protocol-defined stopping criteria is met.
Trial: NCT01945762
Drug: Vandetanib 300 mg
RxNorm normalized name: vandetanib 300 MG
DrugBank: Vandetanib (DB05294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vandetanib commercial tablets
Trial: NCT04048850
Drug: Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet [ZEPATIER]
RxNorm normalized name: Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet [ZEPATIER]
DrugBank: Elbasvir (DB11574)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily medication
Trial: NCT03727802
Drug: TRK-250
RxNorm normalized name: TRK-250
DrugBank: TRK-250 (DB18500)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single and multiple doses (4 weeks)
Trial: NCT03377543
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 81mg aspirin pill daily at bedtime over a 25 day period
Trial: NCT01254136
Drug: Vinorelbine
RxNorm normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: INCB007839 tablets (300 mg BID) in combination with trastuzumab and vinorelbine will be administered in an initial Cycle of 28 days and followed by continuous 21-day cycles subsequently. Trastuzumab will be administered in continuous 21-day cycles beginning on Day 8 of Cycle 1. Vinorelbine will be administered on a weekly schedule for a minimum of the first four cycles beginning on Cycle 1 Day 8. All drugs will be administered continuously as tolerated or until a protocol-defined stopping criteria is met.
Trial: NCT04429542
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: anti-PD-1
Trial: NCT00278213
Drug: fludarabine phosphate
RxNorm normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00278213
Drug: mitoxantrone hydrochloride
RxNorm normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00078715
Drug: Yohimbine hydrochloride
RxNorm normalized name: Yohimbine Hydrochloride
DrugBank: Yohimbine (DB01392)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants receive yohimbine 0.125 mg/kg administered over 3 minutes during REM sleep.